Covered uses of circulating tumor DNA (ctDNA) / plasma testing when ALL listed conditions for each indication are met as specified in individual items below.
BRCA1/2 in ovarian/fallopian tube/primary peritoneal cancer: ctDNA BRCA1/2 variant analysis may be considered medically necessary to select FDA‑approved targeted therapies when tumor tissue analysis is not clinically feasible and follow‑up tissue analysis is planned if no driver is found.
DD.3; EE.1
EGFR exons 19–21 at diagnosis in advanced NSCLC: At diagnosis, plasma ctDNA analysis for EGFR exons 19–21 using an FDA‑approved plasma CDx may be considered medically necessary as an alternative to tissue to select FDA‑approved EGFR therapy when agent/test used per FDA label.
DD.4; cobas EGFR v2 plasma CDx referenced
EGFR T790M at progression for osimertinib: At progression, plasma ctDNA testing for EGFR T790M with an FDA‑approved plasma CDx may be considered medically necessary to select osimertinib when tissue biopsy is not feasible and agent/test used per label.
DD.5
ESR1 for elacestrant in HR+/HER2- advanced breast cancer: ESR1 ctDNA testing may be considered medically necessary to predict response to elacestrant after progression on ≥1 endocrine therapy when agent/test used per FDA label.
DD.6; Guardant360 CDx and other plasma CDx referenced
BRCA1/2 and ATM for mCRPC: ctDNA testing for BRCA1, BRCA2, and ATM to select targeted therapies in mCRPC may be considered medically necessary when using FDA‑approved plasma CDx and agent use is label‑consistent.
DD.7; FoundationOne Liquid CDx entries
MET exon 14 skipping in NSCLC: Plasma ctDNA testing for alterations causing MET exon 14 skipping via an FDA‑approved plasma CDx may be considered medically necessary as an alternative to tissue to select MET inhibitors when agent/test used per FDA label.
DD.8
NTRK gene fusions across multiple tumor types: Plasma ctDNA testing for NTRK fusions using an FDA‑approved plasma CDx may be considered medically necessary as an alternative to tissue to select TRK inhibitors in specified metastatic solid tumors when agent/test used per FDA label.
DD.9; FoundationOne Liquid CDx referenced
PIK3CA in HR+/HER2- advanced breast cancer for alpelisib: PIK3CA ctDNA testing may be considered medically necessary to select alpelisib after progression on endocrine therapy; tissue testing preferred when available but not required.
DD.10; therascreen PIK3CA kit referenced
KRAS/RAS in metastatic CRC: Plasma ctDNA testing for KRAS/RAS variants using an FDA‑approved plasma CDx may be considered medically necessary as an alternative to tissue to select FDA‑approved therapy in metastatic CRC when agent/test used per FDA label.
DD.11
KRAS G12C for sotorasib in advanced lung adenocarcinoma: Plasma ctDNA testing for KRAS G12C via an FDA‑approved plasma CDx may be considered medically necessary as an alternative to tissue to select sotorasib when agent/test used per FDA label.
DD.12; Agilent/Resolution ctDNA assays referenced
ROS1 rearrangements in NSCLC: Plasma ctDNA testing for ROS1 rearrangements may be considered medically necessary as an alternative to tissue to select ROS1 inhibitor therapy when agent/test used per FDA label.
DD.14
Plasma testing when tissue insufficient: Plasma testing for oncogenic driver variants deemed medically necessary on tissue may be used when the individual lacks sufficient tissue for standard molecular testing AND follow‑up tissue‑based analysis is planned if plasma testing finds no driver variant.
EE.1